Eli lilly soars on weight-loss wins, but access fears loom

Eli Lilly's financial performance in early 2026 has been nothing short of stellar, with Q1 revenue soaring 56% year-over-year and non-GAAP earnings per share reaching $8.55 despite acquisition-related R&D charges. This robust momentum prompted the company to raise its full-year 2026 revenue guidance by $2 billion to a range of $82 billion to $85 billion, alongside an EPS forecast between $35.50 and $37, underscoring strong profitability and investor confidence.

The company’s disciplined capital allocation strategy is evident in its substantial shareholder returns, distributing $1.5 billion in dividends and repurchasing $2.4 billion in shares during Q1, while maintaining impressive gross margins of 82.6%. Such financial stewardship complements Lilly’s operational strength, reinforcing its market position and fueling stock momentum.

Eli Lilly’s international expansion is a key driver of its overall growth, with China and broader Asian markets delivering extraordinary revenue increases of 93% and 136% respectively in constant currency. This global footprint, coupled with a dominant 55% share in the international incretin market, bolsters Lilly’s revenue base and supports raised guidance that factors in seasonal and market dynamics rather than conservative forecasting.

Q2 2026 results continued the upward trajectory, with revenue growth of 48% year-over-year fueled by blockbuster incretin drugs like Zepbound and Mounjaro generating $14.9 billion and contributing $6.3 billion to growth. Gross margins further improved to 86.3%, and despite a $3.03 per share hit from acquired R&D charges, non-GAAP EPS remained strong at $8.38. Additionally, the launch of Foundayo, an oral GLP-1, is gaining rapid traction internationally, signaling promising future revenue streams.

Eli Lilly has solidified its competitive position in the obesity and diabetes treatment market through a rapidly expanding portfolio that includes Zepbound, Mounjaro, and Foundao, with prescriber counts for Foundao surging from 8,000 to 36,000 within a quarter and monthly volumes nearly doubling by mid-2026. This momentum is bolstered by strategic international growth, exemplified by $31 million in quarterly Foundao sales in the UAE alone, signaling strong global demand ahead of broader rollout plans. Meanwhile, Lilly’s proactive approach to patient access, such as its expanded access program for the late-stage triple agonist retatrutide, underscores confidence in its pipeline’s potential to reshape weight-loss treatment paradigms.

At the forefront of Lilly’s innovation is retatrutide, a triple agonist that delivered an unprecedented 30.3% average body weight loss over two years in the TRIUMPH-1 trial, positioning it as the most effective injectable obesity drug in late-stage development. Complementing this, the pipeline drug Rita Truetide has demonstrated weight loss approaching bariatric surgery levels in three positive Phase 3 trials, with a US regulatory submission targeted for early 2027. Lilly’s pursuit of biologic classification for Rita Truetide aims to secure regulatory and exclusivity advantages, further strengthening its competitive moat against rivals like Novo Nordisk.

Eli Lilly’s competitive edge is also highlighted by direct clinical comparisons, where its Zepbound outperformed Novo Nordisk’s CagriSema in the REDEFINE 4 trial, with CagriSema failing to demonstrate noninferiority for weight loss. This head-to-head victory, combined with an ambitious pipeline featuring seven additional Phase 3 readouts expected in 2026, underscores Lilly’s sustained innovation and leadership in the obesity treatment space. While diversifying through acquisitions in infectious disease vaccines and psychiatry, Lilly remains firmly focused on consolidating its position against Novo Nordisk in the lucrative weight-loss market.

Eli Lilly's stock price, hovering around $1,160 per share, has sparked speculation about a potential stock split, a move the company hasn't made in nearly three decades. While stock splits historically do not alter company fundamentals, recent examples like Broadcom and Nvidia suggest that any post-split gains are more likely fueled by robust growth catalysts and strong fundamentals. Eli Lilly’s impressive 58% surge over the past year, driven by its expanding GLP-1 weight loss drug portfolio including Foundayo and strategic moves into immunology such as the $2.9 billion Merida Biosciences acquisition, positions it well to sustain momentum regardless of a split.

Investor enthusiasm for Eli Lilly is underscored by high-profile billionaire activity, with Stanley Druckenmiller initiating a new position and Ken Griffin’s Citadel Advisors boosting its stake by 291% to a $1.1 billion holding in Q2 2026. This surge in buying coincided with a notable 23% dip from the stock’s previous high in late April, suggesting these savvy investors capitalized on a strategic entry point. Their confidence is clearly tied to Lilly’s dominant position in the diabetes and obesity markets, particularly the soaring sales of Mounjaro and Zepbound, which continue to drive exceptional revenue and earnings growth alongside promising pipeline candidates like Foundayo.

Despite Eli Lilly's robust financial performance, including higher revenue and raised full-year guidance, investor sentiment has been dampened by growing concerns over insurance coverage for GLP-1 obesity drugs. A recent employer-benefits survey reveals increasing selectivity among companies in covering weight management treatments, signaling potential payer-imposed limits that could slow volume growth and weigh on stock performance.

Employer pushback is becoming more pronounced, exemplified by PepsiCo's decision to drop coverage for certain weight-loss drugs later this year, highlighting the cost sensitivity surrounding these therapies. This move underscores a broader trend of employers scrutinizing the financial impact of covering expensive obesity treatments, which adds to the uncertainty around reimbursement and patient access.

Access to Eli Lilly's weight-loss drugs is further hindered by significant delays stemming from manufacturing constraints and insurance hurdles. Despite tirzepatide's market approval two years ago, supply shortages persist, and newer drugs like zepbound face backorders. Compounding these challenges, many American health plans still do not recognize obesity as a disease, with reviews such as Cigna United Formulary potentially adding another year before coverage decisions are finalized.

The steep cost of GLP-1 drugs, with semaglutide nearing $1,300 per month and retatrutide expected to be even pricier, presents a formidable barrier to widespread insurer willingness and patient access. This pricing dynamic intensifies reimbursement risks and may prompt payers to impose stricter coverage criteria, further complicating the pathway from regulatory approval to actual treatment availability.